Navigation Links
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
Date:11/25/2008

FRAZER, Pa. and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and ImmuPharma PLC (LSE: IMM), a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the investigational medication Lupuzor(TM) for the treatment of Systemic Lupus Erythematosus. ImmuPharma is now conducting a large Phase IIb study of Lupuzor in patients in Europe and Latin America.

Under the terms of the option agreement, Cephalon will pay ImmuPharma a $15 million upfront option payment. If the Phase IIb studies are successful and if the option is exercised then the parties enter into an exclusive worldwide license agreement and ImmuPharma will receive a one-time license fee, milestone payments upon the achievement of regulatory milestones and royalties on commercial sales of Lupuzor. The various milestone payments which include sales milestones may total up to $500 million. Upon exercise of the option, Cephalon will assume all expenses for Phase III studies and subsequent commercialization of the product.

"We are excited about entering another specialty market and the potential Lupuzor presents for us to further diversify our product portfolio and to bring the first specific medication for the treatment of lupus to patients living with this chronic, potentially life-threatening disease," said Frank Baldino, Jr., Ph.D. chairman and CEO of Cephalon. "Our current cash position has created the opportunity to make this type of deal, which helps to position Cephalon and our pipeline for longer term growth."

"We are truly delighted to have this agreement with Cephalon and believe they would be a great partner to take Lupuzor forward. It represents an important landmark for the company and secur
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
2. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
3. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
4. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
5. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
6. Cephalon Conference Call Invitation
7. Cephalon Reports Strong First Quarter Earnings
8. Cephalon Appoints Gerald J. Pappert as General Counsel
9. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
10. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
11. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... The global HCIT outsourcing market is forecast ... $50.4 billion by 2018 from $35 billion in 2013. ... industry are driving the HCIT outsourcing market. These industries ... on core business, reduce operational and maintenance costs, increase ... hiring and training costs), share risk, and quickly implement ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
(Date:10/22/2014)... Pittsburgh, Pennsylvania (PRWEB) October 22, 2014 ... fear and uncertainty among parents and athletes at all ... is working to change the current discussion where two ... there are evidence-based therapies that result in full recoveries ... discussion to one based in fact and research, UPMC ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... ... ... , ... , ...
... ... Jackson & Coker as President of Permanent Recruitment. , ... Alpharetta, GA (Vocus) March 8, 2010 -- Jackson ... the firm’s Permanent Placement Division., , ,“We are pleased that Tony accepted the offer ...
... ... scheduling software. Hakuna understands that in medical emergencies there is no time to be ... the right nurse, ambulance driver, EMT, or doctor scheduled for each shift. , ... (PRWEB) March 8, 2010 -- Hakuna is ...
... New ingredient makes ... ... Relief announced the launch of a new pain relief formula containing HEPES Ester, a patented, ... and swelling of inflamed muscle and joint tissue. This is good news for an estimated ...
... engineers developed a computer-controlled, motorized hand and arm support that will ... over a wider area than otherwise possible, and with less fatigue. ... "We,ve invented a new device the Active Handrest ... their hands such as surgery, painting, electronics repair or other tasks ...
... A new study has found that one in three ... deciding about treatment options felt they did not fully ... and their risk of recurrence. About one in four ... Published early online in CANCER, a peer-reviewed journal of ...
Cached Medicine News:Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 2Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 3Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 4Health News:Survey Reveals Health Insurance and Access to Care Not So Closely Linked 5Health News:Jackson & Coker Names Tony Stajduhar as President of Permanent Recruitment 2Health News:Jackson & Coker Names Tony Stajduhar as President of Permanent Recruitment 3Health News:Hakuna Medical Staff Scheduling Software 2Health News:Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula 2Health News:Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula 3Health News:A high-tech handrest 2Health News:A high-tech handrest 3Health News:A high-tech handrest 4Health News:A high-tech handrest 5Health News:Improvements needed in genomic test result discussions 2
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... 2014 Investor-Edge has initiated coverage ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
... SAN DIEGO, Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... completed the previously announced sale of 17,857,143 shares of ... gross proceeds of approximately $5.0 million, before deducting placement ... and accredited investors participating in the offering purchased the ...
... Bionovo, Inc. (OTC Link Platform: BNVI.PK) a pharmaceutical company ... effective treatments for women,s health and cancer, announced today ... February 21, 2012 at 1:30 PM PST to discuss ... 31, 2011. (Logo:  http://photos.prnewswire.com/prnh/20111110/SF04662LOGO ) ...
Cached Medicine Technology:Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
... Mini Step™ device components are supplied sterile. , ... System is supplied sterile in 2/3, 5, 7/8, ... configurations and combinations. They are used in conjunction ... the Step™ radially Expandable Sleeve. The 5, 7/8, ...
... contains an internal seal to prevent gas leakage ... of pneumoperitoneum. The 5 mm PLUS system includes ... mm - 12 mm as appropriate and is ... of the trocar to allow insertion of smaller ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
Medicine Products: